BioSpace News Archive

Merck KGaA, Darmstadt, Germany announced the conclusion of a joint development agreement to develop and implement a new solution that offers never-before-seen levels of digital trust in machine-to-machine -connected industrial value chains.

REGENXBIO Inc. (Nasdaq: RGNX) today announced financial results for the third quarter ended September 30, 2022, and recent operational highlights.

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the third quarter ended September 30, 2022 and provided recent corporate updates.

Virios Therapeutics, Inc. announced today that its third quarter 2022 financial results will be reported on Monday, November 14, 2022 before the open of the financial markets.

Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, today announced financial results for the third quarter ended September 30, 2022 and provided a corporate update.

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today reported results for the quarter ended September 30, 2022.

Elucid, Inc today announced the addition of Michael D. Lesh, MD, FACC, to its Board of Directors.

Kane Biotech Inc. (TSX-V:KNE OTCQB:KNBIF) (the “Company” or “Kane Biotech”) announces that it has recently submitted a 510(k) premarket notification, which has been received by The Center for Devices and Radiological Health (CDRH) of the U.S. Food and Drug Administration (“FDA”), for a new Wound Care coactiv+™ Antimicrobial Hydrogel.

Aptinyx Inc. today announced the finalization of a $5.6 million grant under the National Institutes of Health (NIH) Helping to End Addiction Long-term (HEAL) Initiative, supporting the development of NYX-783 for the treatment of opioid use disorder (OUD).

Medable Inc. today announced the availability of its Total Consent offering, a fully enabled SaaS electronic consent management solution compatible with every clinical trial, in more than 120 locales around the globe.